Roche (SWX: RO), the Swiss pharmaceutical giant, has announced that it has received an additional indication approval from the National Medical Products Administration (NMPA) for its drug Alecensa (alectinib). This new indication is for use as a post-surgery adjuvant therapy in patients with stage 1B to stage IIIA non-small cell lung cancer (NSCLC) that tests positive for anaplastic lymphoma kinase (ALK).
Alectinib, a next-generation ALK inhibitor, was initially approved for the treatment of ALK-positive locally advanced or metastatic NSCLC. With this new approval, the drug now becomes the first ALK-TKI to cover both early-stage and advanced NSCLC, marking a significant expansion in its therapeutic applications.- Flcube.com
